Sparta Commercial Services (SRCO) 10-Q/A 27 Mar 23 2023 Q3 Quarterly report (amended) Financial data

Cover

Cover - shares	9 Months Ended
	Jan. 31, 2023	Mar. 22, 2023
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	The purpose of this Amendment No. 1 (this “Amendment”) to our Quarterly Report on Form 10-Q for the period ended January 31, 2023 (the “Form 10-Q”), as filed with the Securities and Exchange Commission (the “SEC”) on March 22, 2023, is to correct certain technical and typographical errors in the interim Financial Statements and accompanying Notes to Interim Financial Statements, to furnish subsequent adjustments to the financial statements for the 3-month period ended January 31, 2022 due to clerical errors, and the Inline eXtensible Business Reporting Language (iXBRL) data.
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--04-30
Entity File Number	0-9483
Entity Registrant Name	SPARTA COMMERCIAL SERVICES, INC.
Entity Central Index Key	0000318299
Entity Tax Identification Number	30-0298178
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Fifth Avenue
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(212)
Local Phone Number	239-2666
Title of 12(b) Security	Common stock, $.001 par value
Trading Symbol	SRCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		22,021,449

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Current Assets
Cash and cash equivalents	$ 612	$ 317
Accounts receivable	2,169
Inventory	5,256	8,422
Other current assets
Total Current Assets	8,037	8,739
Property and equipment, net of accumulated depreciation and amortization of $213,262 and $213,262, respectively
Deposits - rent deposit	9,000	9,000
Total assets	17,037	17,739
Current Liabilities
Bank overdraft	41,097	27,202
Accounts payable and accrued expenses	1,751,557	1,673,342
Short Term Loan	1,585	1,585
Current portion notes payable	7,139,773	8,070,871
Deferred revenue	8,037	13,385
Derivative liabilities	4,504,762	9,549,640
Total Current Liabilities	13,446,811	19,336,025
Loans payable-related parties	394,753	432,403
Total Long Term Liabilities	394,753	432,403
Total liabilities	13,841,564	19,768,428
Stockholders’ Deficit:
Common stock, $0.001 par value; 750,000,000 shares authorized, and 21,581,449 and 15,128,005 shares issued and outstanding as of January 31, 2023 and April 30, 2022, respectively	21,113	15,128
Common stock to be issued 23,333,438 and 8,916,805 respectively	23,334	8,292
Additional paid-in-capital	54,570,072	53,210,921
Accumulated deficit	(69,448,432)	(73,984,686)
Total deficiency in stockholders’ equity	(14,818,496)	(20,734,864)
Non-controlling interest	993,969	984,175
Total Deficit	(13,824,527)	(19,750,689)
Total Liabilities and Deficit	17,037	17,739
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred Stock Value	12,500	12,500
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred Stock Value	1,979	2,363
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred Stock Value	$ 938	$ 618

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Accumulated depreciation and amortization	$ 213,262	$ 213,262
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock shares issued	21,581,449	15,128,005
Common stock shares outstanding	21,581,449	15,128,005
Common stock to be issued	23,333,438	8,916,805
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares designated	35,850	35,850
Preferred stock, shares issued	125	125
Preferred stock, shares outstanding	125	125
Series C Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	4,200,000	4,200,000
Preferred stock, shares issued	1,979,157	2,363,000
Preferred stock, shares outstanding	1,979,157	2,363,000
Preferred stock, liquidation and redemption value per share	$ 1	$ 1
Series D Redeemable Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	2,000,000	2,000,000
Preferred stock, shares issued	937,754	618,411
Preferred stock, shares outstanding	937,754	618,411
Preferred stock, liquidation and redemption value per share	$ 1	$ 1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2023	Jan. 31, 2022
Revenue
Total Revenue	$ 63,670		$ 189,042	$ 187,103
Less Cost of goods sold	9,142		31,987	32,551
Gross profit	54,528		157,055	154,552
Operating expenses:
General and administrative	403,695		1,239,454	847,017
Research and Development			41,969
Total operating expenses	403,695		1,281,423	847,017
Loss from operations	(349,167)		(1,124,368)	(692,465)
Other (income) expense:
Other income	(473)		(473)	(11,356)
Write off convertible notes	324,969		(625,064)
Financing cost	(2,305)			180,750
Loss (gain) in changes in fair value of derivative liability	(1,757,044)		(5,044,879)	5,990,400
Total other (income) expense	(1,434,852)		(5,670,415)	6,159,794
Net income (loss)	(1,085,686)		4,546,048	(6,852,259)
Net profit attributable to minority shareholder	(3,081)		(9,794)	15,790
Preferred dividend				(382)
Net income (loss) attributed to common stockholders	$ (1,082,605)		$ 4,536,254	$ (6,836,851)
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders				$ (0.55)
Net loss attributable to Sparta Commercial Services, Inc. common stockholders	$ (0.05)		$ 0.25	$ (0.54)
Weighted average shares outstanding	19,686,822		18,074,511	12,568,827
Information Technology [Member]
Revenue
Total Revenue	$ 60,120		$ 173,559	$ 168,933
New World Health Brands [Member]
Revenue
Total Revenue	$ 3,550		$ 15,483	$ 18,170
Previously Reported [Member]
Revenue
Total Revenue		$ 121,405
Less Cost of goods sold		19,435
Gross profit		101,970
Operating expenses:
General and administrative		590,304
Total operating expenses		590,304
Loss from operations		(488,334)
Other (income) expense:
Other income		(3,297)
Write off convertible notes
Financing cost		180,750
Loss (gain) in changes in fair value of derivative liability		1,062,260
Total other (income) expense		1,239,713
Net income (loss)		(1,728,047)
Net profit attributable to minority shareholder		(15,472)
Net income (loss) attributed to common stockholders		$ (1,743,526)
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders		$ (0.13)
Net loss attributable to Sparta Commercial Services, Inc. common stockholders		$ (0.10)
Weighted average shares outstanding		13,265,570
Previously Reported [Member] | Information Technology [Member]
Revenue
Total Revenue		$ 112,691
Previously Reported [Member] | New World Health Brands [Member]
Revenue
Total Revenue		8,714
Revision of Prior Period, Adjustment [Member]
Revenue
Total Revenue		60,720
Less Cost of goods sold		9,258
Gross profit		51,462
Operating expenses:
General and administrative		340,280
Research and Development
Total operating expenses		340,280
Loss from operations		(288,818)
Other (income) expense:
Other income		(3,297)
Financing cost
Loss (gain) in changes in fair value of derivative liability		1,442,908
Total other (income) expense		1,439,611
Net income (loss)		(1,728,429)
Net profit attributable to minority shareholder		(15,452)
Preferred dividend		(382)
Net income (loss) attributed to common stockholders		$ (1,744,263)
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders		$ (0.4300)
Net loss attributable to Sparta Commercial Services, Inc. common stockholders		$ (0.13)
Weighted average shares outstanding		13,265,570
Revision of Prior Period, Adjustment [Member] | Information Technology [Member]
Revenue
Total Revenue		$ 56,134
Revision of Prior Period, Adjustment [Member] | New World Health Brands [Member]
Revenue
Total Revenue		$ 4,586

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholder's Deficits - USD ($)	Series A Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Series D Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Common Stock to be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance, value at Apr. 30, 2021	$ 12,500	$ 4,145	$ 1,494	$ 9,810	$ 1,215	$ 51,351,156	$ (64,993,250)	$ 986,999	$ (12,625,931)
Balance, shares at Apr. 30, 2021	125	4,132,269	1,493,962	9,809,877	1,214,528
Issuance of common shares for cash					$ 1,135	98,183			99,318
Issuance of common shares for cash, shares					1,134,697
Net loss (adjusted)							379,802	338	380,140
Issuance of Preferred and Common Stock for Cash		$ (704)	$ (303)	$ 1,574		373,326			373,893
Issuance of Preferred and Common Stock for Cash, shares		(704,300)	(302,551)	1,574,001
Conversion of notes to common shares				$ 125		24,875			25,000
Conversion of notes to common shares, shares				125,000
Balance, value at Jul. 31, 2021	$ 12,500	$ 3,441	$ 1,191	$ 11,509	$ 2,350	51,847,540	(64,613,448)	987,337	(11,747,580)
Balance, shares at Jul. 31, 2021	125	3,427,969	1,191,411	11,508,878	2,349,225
Issuance of common shares for cash				$ 696	$ 22,443	(22,443)			696
Issuance of common shares for cash, shares				696,475	22,442,105
Net loss (adjusted)							(4,759,480)	311	(4,759,169)
Issuance of Preferred and Common Stock for Cash		$ (281)	$ (409)		$ (2,350)	(317,979)			(321,019)
Issuance of Preferred and Common Stock for Cash, shares		(281,000)	(409,000)		(2,349,225)
Balance, value at Oct. 31, 2021	$ 12,500	$ 3,160	$ 782	$ 12,205	$ 22,443	51,507,118	(69,372,928)	987,648	(16,827,072)
Balance, shares at Oct. 31, 2021	125	3,146,969	782,411	12,205,353	22,442,105
Balance, value at Jul. 31, 2021	$ 12,500	$ 3,441	$ 1,191	$ 11,509	$ 2,350	51,847,540	(64,613,448)	987,337	(11,747,580)
Balance, shares at Jul. 31, 2021	125	3,427,969	1,191,411	11,508,878	2,349,225
Conversion of Preferred shares, shares
Balance, value at Oct. 31, 2022	$ 12,500	$ 1,722	$ 477	$ 18,701	$ 10,622	53,933,335	(70,531,037)	990,888	(15,562,792)
Balance, shares at Oct. 31, 2022	125	1,522,000	477,411	18,700,782	11,247,437
Balance, value at Oct. 31, 2021	$ 12,500	$ 3,160	$ 782	$ 12,205	$ 22,443	51,507,118	(69,372,928)	987,648	(16,827,072)
Balance, shares at Oct. 31, 2021	125	3,146,969	782,411	12,205,353	22,442,105
Issuance of shares for services				$ 427		25,063			25,490
Issuance of shares for services, shares				427,235
Net loss (adjusted)							(1,728,047)	(15,452)	(1,743,526)
Conversion of preferred shares		$ (797)	$ (164)	$ 1,841	$ 995	1,295,521		(960)	1,296,436
Conversion of Preferred shares, shares		(983,969)	(164,000)	1,620,417	995,400
Preferred Dividend								(382)	(382)
Balance, value at Jan. 31, 2022	$ 12,500	$ 2,363	$ 618	$ 14,473	$ 23,438	52,827,502	(71,466,089)	971,827	(17,614,168)
Balance, shares at Jan. 31, 2022	125	2,163,000	618,411	14,253,005	23,437,605
Balance, value at Apr. 30, 2022	$ 12,500	$ 2,363	$ 618	$ 15,128	$ 8,292	53,210,921	(73,984,686)	984,175	(19,750,689)
Balance, shares at Apr. 30, 2022	125	2,163,000	618,411	15,128,005	8,916,805
Conversion of Preferred to common shares		$ (60)		$ 60		9,940			9,940
Conversion of Preferred to common shares, shares		(60,000)		60,000
Issuance of common shares for cash					$ 1,824	93,175			94,999
Issuance of common shares for cash, shares					1,824,771
Issuance of shares for services				$ 1,595		243,786			245,381
Issuance of shares for services, shares				1,594,960
Stocks issued for equity				$ 518		44,128			44,646
Stocks issued for equity, shares				518,333
Net loss (adjusted)							1,101,351	3,924	1,105,275
Balance, value at Jul. 31, 2022	$ 12,500	$ 2,303	$ 618	$ 17,301	$ 10,116	53,601,950	(72,883,335)	988,099	(18,250,448)
Balance, shares at Jul. 31, 2022	125	2,103,000	618,411	17,301,298	10,741,576
Balance, value at Apr. 30, 2022	$ 12,500	$ 2,363	$ 618	$ 15,128	$ 8,292	53,210,921	(73,984,686)	984,175	(19,750,689)
Balance, shares at Apr. 30, 2022	125	2,163,000	618,411	15,128,005	8,916,805
Balance, value at Jan. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 21,113	$ 23,334	54,570,072	(69,448,432)	993,969	(13,824,527)
Balance, shares at Jan. 31, 2023	125	1,979,157	937,754	21,581,449	23,333,438
Balance, value at Jul. 31, 2022	$ 12,500	$ 2,303	$ 618	$ 17,301	$ 10,116	53,601,950	(72,883,335)	988,099	(18,250,448)
Balance, shares at Jul. 31, 2022	125	2,103,000	618,411	17,301,298	10,741,576
Issuance of common shares for cash				$ 135	$ 506	49,359			50,000
Issuance of common shares for cash, shares				134,805	505,861
Net loss (adjusted)							2,352,298	2,789	2,355,087
Conversion of Preferred to common shares C		$ (581)		$ 581		96,915			96,915
Conversion of Preferred to common shares C, shares		(581,000)		581,000
Conversion of Preferred to common shares D			$ (141)	$ 141		141,053			141,053
Conversion of Preferred to common shares D, shares			(141,000)	141,000
Stocks issued as note holder incentive				$ 213		19,388			19,601
Stocks issued as note holder incentive, shares				212,500
Issuance of shares for equity				$ 330		24,670			25,000
Issuance of shares for equity, shares				330,179
Balance, value at Oct. 31, 2022	$ 12,500	$ 1,722	$ 477	$ 18,701	$ 10,622	53,933,335	(70,531,037)	990,888	(15,562,792)
Balance, shares at Oct. 31, 2022	125	1,522,000	477,411	18,700,782	11,247,437
Issuance of shares for services				$ 334		37,261			37,595
Issuance of shares for services, shares				333,939
Net loss (adjusted)							1,082,605	3,081	1,085,686
Issuance of shares for equity				$ 952		83,098			84,050
Issuance of shares for equity, shares				952,036
Conversion of preferred shares		$ (1,922)		$ 747	$ 1,175.10	190,103			190,103
Conversion of Preferred shares, shares		(1,922,101)		747,000	1,175,101
Issuance for Notes payable				$ 379		34,160			34,539
Issuance for notes payable, shares				378,909
Reconciling shares		$ 2,179	$ 461		$ 11,537	315,863			330,040
Adjustment, shares		2,379,258	460,343	468,783	10,910,900
Balance, value at Jan. 31, 2023	$ 12,500	$ 1,979	$ 938	$ 21,113	$ 23,334	$ 54,570,072	$ (69,448,432)	$ 993,969	$ (13,824,527)
Balance, shares at Jan. 31, 2023	125	1,979,157	937,754	21,581,449	23,333,438

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income ( loss )	$ 4,546,048	$ (6,852,259)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		262,466
Loss (Gain) from change in fair value of derivative liabilities	(5,044,879)	5,990,400
Amortization of debt discount		40,000
Non-cash financing cost		180,750
Non-cash consulting fees	2,480	90,448
Write off promissory notes	(625,064)	(190,186)
Changes in operating assets and liabilities
Accounts receivable	(2,168)	(2,273)
Inventory	3,166	3,844
Accounts payable and accrued expenses	78,215	15,736
Deferred revenue	(5,348)	(8,432)
Net cash used in operating activities	(1,047,550)	(469,506)
CASH FLOWS FROM INVESTING ACTIVITIES:
CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft	13,895	626
Proceeds from sale of stock	135,000	407,500
Payments on notes payable		(267,428)
Proceeds from related party notes
Payments on related party notes	(37,650)
Conversion of promissory notes	936,600	359,123
Net cash provided by financing activities	1,047,845	499,821
Net (decrease) increase in cash	295	30,315
Cash and cash equivalents, beginning of period	317	396
Cash and cash equivalents, end of period	612	30,711
Cash paid for:
Interest
Income taxes

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows. Business General Overview Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City, www.spartacommercial.com www.spartacommercial.com Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis, in 2007, the Company introduced a new initiative, Municipal Financing ( www.spartamunicipal.com Consumers, retailers, municipals, nonprofits, auction houses, banks, and insurance companies scrutinize title history reports for the vital information needed and factored into crucial business decisions affecting the bottom line. Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness. They have been sold across all 50 states and in 62 countries worldwide. They provide a trusted layer of assurance to vehicle buyers and are available on our websites as well as on various dealership websites. They include Cyclechex (Motorcycle History Reports at www.cyclechex.com www.rvchex.com www.truckchex.com The Company’s E-Commerce and Mobile Technology subsidiary name change to iMobile Solutions, Inc., from Specialty Reports, Inc., in 2016, signifies its ever-broadening service offerings in the evolving technology landscape. With iMobile App ( www.imobileapp.com www.imobileapp.com/app-gallery We provide specific, tailored action plans for our clients’ websites that include services such as eCommerce, CRM (Customer Relationship Management) development, and integration. This custom software helps businesses communicate with customers and can also be used for employees to communicate internally. The CRM software can be web-based, integrated with a mobile app, or both. We work with clients to understand their unique needs and incorporate the features and requirements that are most important to them and will facilitate their business growth and success. Correspondingly, the Company designs and builds custom kitchen ordering software for independent grocery stores, delicatessens, and other food service businesses. The software can be designed in various ways, including mobile devices and in-store ordering. The kitchen ordering software is enabled with payment integration, text messaging notification, wireless printing, and other features. iMobile Solutions, Inc. provides a turn-key solution for businesses looking to simplify or streamline their kitchen ordering process. Additionally, we offer text messaging services, which supplement business marketing strategies to gain and retain brand loyalty among its clients, customers, and investors. Our text messaging platform allows clients to manage, schedule, and analyze text message performance quickly. Company management recognized the substantial business opportunity in the rapidly expanding hemp-CBD (cannabidiol) market in the United States. Sparta created its subsidiary, New World Health Brands, Inc., in April 2019, on the heels of the Agriculture Improvement Act (also known as the Farm Bill), signed into law last December 20, 2018. Consequently, regulators removed hemp (CBD) from Schedule 1 of the Controlled Substances Act. During 2019-2020, we sourced, developed, and tested 5 CBD product categories totaling 31 products. We procured premium, domestic-grade, full-spectrum, broad-spectrum, and THC-free hemp, created product packaging and labeling, and implemented fulfillment to launch an online Business-to-Consumer (“B to C”) website: www.newworldhealthcbd.com Sparta’s response to the onset of the COVID-19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com Sparta’s subsidiary, Sparta Crypto, Inc., www.SpartaCrypto.com, was established on September 25, 2020, and is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services. The platform has not launched and the Company can make no assurances that the described plan will reach implementation. In addition, the Company has completed and tested a cryptocurrency payment gateway called SpartaPayIQ, www.SpartaPayIQ.com Agoge Global USA, Inc. was formed as a subsidiary of Sparta Crypto, Inc. in December 2022 and entered in to a Joint Venture Agreement with WeDev Group to facilitate cross-border transactions between importers and exporters of goods from the U.S. and Brazil. In addition, Agoge Global USA provides business intermediary services to global importers and exporters of goods and services. These services include, but are not limited to, industry introductions, tax compliance assistance, import and export documentation assistance, reselling services in other jurisdictions, and facilitation of cross-border transactions. Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2023, and for the nine months ended January 31, 2023, and 2022 have been prepared by the Company according to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to present the operating results for the respective periods fairly. Certain information and footnote disclosures usually present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted under such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented accurate. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2022, as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission on August 15, 2022. The results of operations for the nine months ended January 31, 2022, are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2023. The condensed consolidated balance sheet as of April 30, 2022, contained herein has been derived from the audited consolidated financial statements as of April 30, 2022, but does not include all disclosures required by the U.S. GAAP. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit. Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the said period. Accordingly, actual results could differ from those estimates. Revenue Recognition During the first quarter of 2018, the Company adopted A.S.U. 2014-09, Revenue from Contracts with Customers (Topic 606) The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2023 Jan 2022 (Adjusted) Jan 2023 Jan 2022 Information technology $ 60,120 $ 56,134 $ 173,559 $ 168,933 New World Health $ 3,550 $ 4,586 $ 15,483 $ 18,170 Total 63,670 60,720 189,042 187,103 Revenues from mobile app products and New World Health Brands products are generally recognized upon delivery. Revenues from History Reports are typically recognized upon delivery/download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. The Company records deferred revenues when cash payments are received or due before our performance, including refundable amounts. Cash Equivalents All liquid investments with three months or less maturity are cash equivalents for the accompanying financial statements. Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data when available and to minimize the use of unobservable inputs when determining fair value. Observable inputs may not always be available for some products or in certain market conditions. Income Taxes We utilize ASC 740, “ Income Taxes The Company recognizes the impact of a position in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. Our practice recognizes interest or penalties related to income tax matters in income tax expense. Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation–Stock Compensation We use the fair value method for equity instruments granted to non-employees and the Black-Scholes model to measure options’ fair value. The stock-based fair value compensation is determined as of the date of the grant or at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Inventories The Company’s inventories represent finished goods, consisting of available products. They are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business. Property and Equipment Property and equipment are recorded at cost. Minor additions and renewals are expensed in the year incurred. Significant additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is calculated using the straight-line method over the estimated useful lives. The estimated useful lives of significant depreciable assets are as follows: SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, and receivables. The Company places its cash and temporary cash investments with high-credit quality institutions. At times, such investments may be more than the FDIC insurance limit. Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share As of January 31, 2023, and April 30, 2022, approximately 32,350,243 23,333,438 8,916,805 Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2023, and April 30, 2022, which consist of convertible instruments and rights to shares of the Company’s common stock. It determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed conventional, as described. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control and could or require net cash settlement, then the contract shall be classified as an asset or a liability. The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features Reclassifications Certain reclassifications have been made to conform with prior periods’ data to the current presentation. These reclassifications did not affect reported losses. Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02 Leases Leases Standard-setting organizations and various regulatory agencies are currently studying multiple proposed or potential accounting standards. Due to the tentative and preliminary nature of those proposed standards, we have yet to determine whether implementation of such proposed standards would be material to our consolidated financial statements and other disclosures as included in the footnotes to the financial statements.

GOING CONCERN MATTERS

GOING CONCERN MATTERS	9 Months Ended
	Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN MATTERS	NOTE B – GOING CONCERN MATTERS The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company has incurred recurring losses and generated negative cash flows from operating activities since inception. As of January 31, 2023, the Company had an accumulated deficit of $ 69,448,432 73,984,686 13,438,774 19,327,286 The Company’s existence depends on management’s ability to develop profitable operations. Management is devoting substantially all its efforts to growing its business and raising capital, and there can be no assurance that the Company’s efforts will be successful. The management’s actions are not guaranteed to result in profitable operations or resolve liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company’s management actively pursues additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

NOTES PAYABLE AND DERIVATIVES

NOTES PAYABLE AND DERIVATIVES	9 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE AND DERIVATIVES	NOTE C – NOTES PAYABLE AND DERIVATIVES The Company has numerous outstanding notes payable to various parties. The notes bear interest at rates of 5% - 20% per year and are summarized as follows: SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2023 April 30, 2022 Notes convertible at holder’s option $ 3,042,773 $ 2,980,848 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 2,077,981 1,933,536 Subtotal 5,456,454 5,250,084 Total $ 5,456,454 $ 5,250,084 The balance of accrued interest of the above notes as of January 31, 2023, and April 30, 2022, were $ 1,656,450 2,680,787 1,024,337 Certain notes payable contain variable conversion rates, and the conversion features are classified as derivative liabilities. The conversion prices are based on the market price of the Company’s common stock, at discounts of 30% 48% The Company’s derivative financial instruments are embedded derivatives related to the outstanding short-term Convertible Notes Payable. These embedded derivatives included certain conversion features indexed to the Company’s common stock. The accounting treatment of derivative financial instruments requires that the Company record the derivatives and related items at their fair values as of the inception date of the Convertible Notes Payable and at fair value as of each subsequent balance sheet date. In addition, under the provisions of Accounting Standards Codification subtopic 815-40, Derivatives and Hedging; Contracts in Entity’s Own Equity (“ASC 815-40”), as a result of entering into the Convertible Notes Payable, the Company is required to classify all other non-employee stock options and warrants as derivative liabilities and mark them to market at each reporting date. Any change in fair value, including modifications of terms, will be recorded as non-operating, non-cash income, or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the products is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income. These Notes are subject to a six The change in fair value of the derivative liabilities on January 31, 2023, was calculated with the following average assumptions using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk-free interest rate Ranging from 0.16% 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout 0 Expected life in years Ranging from 0.25 3.0 Expected life in years Ranging from 0.25 3.0 Changes in derivative liability during the three months ended January 31, 2023, and April 30, 2022 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES 2023 2022 January 31, April 30, 2023 2022 Balance, beginning of year $ 9,549,640 $ 3,446,738 Derivative liability extinguished (336,418 ) (1,029,141 ) Derivative financial liability arising on the issuance of convertible notes and warrants - Fair value adjustments (4,168,344 ) 7,132,043 Balance, end of period $ 4,504,762 $ 9,549,640

LOANS PAYABLE TO RELATED PARTIE

LOANS PAYABLE TO RELATED PARTIES	9 Months Ended
	Jan. 31, 2023
Related Party Transactions [Abstract]
LOANS PAYABLE TO RELATED PARTIES	NOTE D – LOANS PAYABLE TO RELATED PARTIES As of January 31, 2023, and April 30, 2022, aggregated loans and notes payable, without demand and with no interest, to officers and directors were $ 371,753 409,403

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	9 Months Ended
	Jan. 31, 2023
Equity [Abstract]
EQUITY TRANSACTIONS	NOTE E EQUITY TRANSACTIONS Preferred Stock The Company is authorized to issue 10,000,000 0.001 35,850 100 1,000 10,000 4,200,000 1.00 2,000,000 1.00 During the nine months ending January 31, 2023. ● Converted total of 1,738,258 231,396 ● Converted a total of 141,053 141,053 During the nine months ended January 31, 2022, the Company: ● Converted a total of 1,969,269 373,893 ● Converted a total of 3,194,418 975,217 Common Stock The Company is authorized to issue 750,000,000 0.001 21,581,449 15,128,005 During the nine months ended January 31, 2023, the Company: ● Sold 3,102,346 212,500 ● Issued 330,179 ● Issued 1,388,376 ● Issued 564,212 ● Issued 950,833 83,447 ● Issued 378,909 35,000 ● Issued 1,928,899 282,981 During the nine months ended January 31, 2023, the Company: Sold to six accredited investors 2,726,036 shares of common stock for cash of $ 182,500

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE F – FAIR VALUE MEASUREMENTS The Company follows the guidelines established according to ASC 820, which established a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 defines fair value as the amount received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes the following three levels of inputs that may be used: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs. The table below summarizes the fair values of financial liabilities as of January 31, 2023: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2023 Level 1 Level 2 Level 3 Derivative liabilities $ 4,504,762 - - $ 4,504,762 Fair values of financial liabilities as of April 30, 2022, are as follows: Fair Value at Fair Value Measurement Using April 30, 2022 Level 1 Level 2 Level 3 Derivative liabilities $ 9,549,640 - - $ 9,549,640 The following is a description of the valuation methodologies used for these items: Derivative liabilities The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value following A.S.C. Topic 825, “ The Fair Value Option for Financial Issuances

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Jan. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE G – PROPERTY AND EQUIPMENT Significant classes of property and equipment on January 31, 2023, and April 30, 2022, consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT January 31, 2023 April 30, 2022 Computer equipment, software and furniture $ 213,262 $ 213,262 Less: accumulated depreciation (213,262 ) (213,262 ) Net property and equipment $ - $ - All equipment is fully depreciated as of January 31, 2023, and 2022. No additional investment in equipment for both fiscal years.

WARRANTS

WARRANTS	9 Months Ended
	Jan. 31, 2023
Warrants
WARRANTS	NOTE H – WARRANTS No warrants were issued to employees or services. As of January 31, 2023 , a total of 9,229,370 211,614

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I – COMMITMENTS AND CONTINGENCIES Operating Lease Commitments Our executive offices are located in New York, NY. We have an agreement for use of office space at this location under a sublease which expired on July 31, 2018 5,100 Rent expense was $ 49,700 43,200 Litigation The Company is subject to legal proceedings and claims arising in its business’s ordinary course. Sparta can make no representations about the potential outcome of such proceedings. As of January 31, 2023, we have not been named as parties to any further legal proceedings except those disclosed prior and updated below. From time to time, we may become involved in other legal proceedings, which sometimes arise due to the very nature of and in the ordinary course of this business. By way of background, the Company had received notices dated April 1, 2016, May 13, 2016, and July 22, 2016, from two lenders claiming defaults relating to conversion requests of $ 8,365.00 5,000.00 55,125.00 27,500.00 For the above claims, on September 22, 2016, a motion for summary judgment instead of complaint was filed in the Supreme Court in the State of New York: County of Kings against the Company by a lender for the amount of $ 102,170.82 On October 26, 2018, a second lender commenced an action in the Supreme Court of the State of New York: New York County alleging damages from unpaid principal arising from a promissory note dated February 26, 2015, in the amount of $ 50,000.00

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jan. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE J – SUBSEQUENT EVENTS The Company had evaluated subsequent events for recognition and disclosure as of March 21, 2023 when the financial statements were available to be issued. The Company’s Board of Directors has approved management’s recommendation to discontinue the canabidiol (CBD) line of business effective March 31, 2023. No other matters were identified affecting the accompanying financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Business	Business General Overview Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City, www.spartacommercial.com www.spartacommercial.com Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis, in 2007, the Company introduced a new initiative, Municipal Financing ( www.spartamunicipal.com Consumers, retailers, municipals, nonprofits, auction houses, banks, and insurance companies scrutinize title history reports for the vital information needed and factored into crucial business decisions affecting the bottom line. Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness. They have been sold across all 50 states and in 62 countries worldwide. They provide a trusted layer of assurance to vehicle buyers and are available on our websites as well as on various dealership websites. They include Cyclechex (Motorcycle History Reports at www.cyclechex.com www.rvchex.com www.truckchex.com The Company’s E-Commerce and Mobile Technology subsidiary name change to iMobile Solutions, Inc., from Specialty Reports, Inc., in 2016, signifies its ever-broadening service offerings in the evolving technology landscape. With iMobile App ( www.imobileapp.com www.imobileapp.com/app-gallery We provide specific, tailored action plans for our clients’ websites that include services such as eCommerce, CRM (Customer Relationship Management) development, and integration. This custom software helps businesses communicate with customers and can also be used for employees to communicate internally. The CRM software can be web-based, integrated with a mobile app, or both. We work with clients to understand their unique needs and incorporate the features and requirements that are most important to them and will facilitate their business growth and success. Correspondingly, the Company designs and builds custom kitchen ordering software for independent grocery stores, delicatessens, and other food service businesses. The software can be designed in various ways, including mobile devices and in-store ordering. The kitchen ordering software is enabled with payment integration, text messaging notification, wireless printing, and other features. iMobile Solutions, Inc. provides a turn-key solution for businesses looking to simplify or streamline their kitchen ordering process. Additionally, we offer text messaging services, which supplement business marketing strategies to gain and retain brand loyalty among its clients, customers, and investors. Our text messaging platform allows clients to manage, schedule, and analyze text message performance quickly. Company management recognized the substantial business opportunity in the rapidly expanding hemp-CBD (cannabidiol) market in the United States. Sparta created its subsidiary, New World Health Brands, Inc., in April 2019, on the heels of the Agriculture Improvement Act (also known as the Farm Bill), signed into law last December 20, 2018. Consequently, regulators removed hemp (CBD) from Schedule 1 of the Controlled Substances Act. During 2019-2020, we sourced, developed, and tested 5 CBD product categories totaling 31 products. We procured premium, domestic-grade, full-spectrum, broad-spectrum, and THC-free hemp, created product packaging and labeling, and implemented fulfillment to launch an online Business-to-Consumer (“B to C”) website: www.newworldhealthcbd.com Sparta’s response to the onset of the COVID-19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com Sparta’s subsidiary, Sparta Crypto, Inc., www.SpartaCrypto.com, was established on September 25, 2020, and is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services. The platform has not launched and the Company can make no assurances that the described plan will reach implementation. In addition, the Company has completed and tested a cryptocurrency payment gateway called SpartaPayIQ, www.SpartaPayIQ.com Agoge Global USA, Inc. was formed as a subsidiary of Sparta Crypto, Inc. in December 2022 and entered in to a Joint Venture Agreement with WeDev Group to facilitate cross-border transactions between importers and exporters of goods from the U.S. and Brazil. In addition, Agoge Global USA provides business intermediary services to global importers and exporters of goods and services. These services include, but are not limited to, industry introductions, tax compliance assistance, import and export documentation assistance, reselling services in other jurisdictions, and facilitation of cross-border transactions.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2023, and for the nine months ended January 31, 2023, and 2022 have been prepared by the Company according to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to present the operating results for the respective periods fairly. Certain information and footnote disclosures usually present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted under such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented accurate. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2022, as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission on August 15, 2022. The results of operations for the nine months ended January 31, 2022, are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2023. The condensed consolidated balance sheet as of April 30, 2022, contained herein has been derived from the audited consolidated financial statements as of April 30, 2022, but does not include all disclosures required by the U.S. GAAP.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit.
Estimates	Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the said period. Accordingly, actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition During the first quarter of 2018, the Company adopted A.S.U. 2014-09, Revenue from Contracts with Customers (Topic 606) The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2023 Jan 2022 (Adjusted) Jan 2023 Jan 2022 Information technology $ 60,120 $ 56,134 $ 173,559 $ 168,933 New World Health $ 3,550 $ 4,586 $ 15,483 $ 18,170 Total 63,670 60,720 189,042 187,103 Revenues from mobile app products and New World Health Brands products are generally recognized upon delivery. Revenues from History Reports are typically recognized upon delivery/download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. The Company records deferred revenues when cash payments are received or due before our performance, including refundable amounts.
Cash Equivalents	Cash Equivalents All liquid investments with three months or less maturity are cash equivalents for the accompanying financial statements.
Fair Value Measurements	Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data when available and to minimize the use of unobservable inputs when determining fair value. Observable inputs may not always be available for some products or in certain market conditions.
Income Taxes	Income Taxes We utilize ASC 740, “ Income Taxes The Company recognizes the impact of a position in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. Our practice recognizes interest or penalties related to income tax matters in income tax expense.
Stock-Based Compensation	Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation–Stock Compensation We use the fair value method for equity instruments granted to non-employees and the Black-Scholes model to measure options’ fair value. The stock-based fair value compensation is determined as of the date of the grant or at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Inventories	Inventories The Company’s inventories represent finished goods, consisting of available products. They are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Minor additions and renewals are expensed in the year incurred. Significant additions and renewals are capitalized and depreciated over their estimated useful lives. Depreciation is calculated using the straight-line method over the estimated useful lives. The estimated useful lives of significant depreciable assets are as follows: SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents, and receivables. The Company places its cash and temporary cash investments with high-credit quality institutions. At times, such investments may be more than the FDIC insurance limit.
Net Loss Per Share	Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share As of January 31, 2023, and April 30, 2022, approximately 32,350,243 23,333,438 8,916,805
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2023, and April 30, 2022, which consist of convertible instruments and rights to shares of the Company’s common stock. It determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed conventional, as described.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control and could or require net cash settlement, then the contract shall be classified as an asset or a liability. The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features
Reclassifications	Reclassifications Certain reclassifications have been made to conform with prior periods’ data to the current presentation. These reclassifications did not affect reported losses.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02 Leases Leases Standard-setting organizations and various regulatory agencies are currently studying multiple proposed or potential accounting standards. Due to the tentative and preliminary nature of those proposed standards, we have yet to determine whether implementation of such proposed standards would be material to our consolidated financial statements and other disclosures as included in the footnotes to the financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF DISAGGREGATION REVENUE	The Company acts as a principal in its revenue transactions as it is the primary obligor. SCHEDULE OF DISAGGREGATION REVENUE 3-months ended 9-months ended Revenue Jan 2023 Jan 2022 (Adjusted) Jan 2023 Jan 2022 Information technology $ 60,120 $ 56,134 $ 173,559 $ 168,933 New World Health $ 3,550 $ 4,586 $ 15,483 $ 18,170 Total 63,670 60,720 189,042 187,103
SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT	SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT Leasehold improvements 3 years Furniture and fixtures 7 years Website costs 3 years Computer Equipment 5 years

NOTES PAYABLE AND DERIVATIVES (

NOTES PAYABLE AND DERIVATIVES (Tables)	9 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE	The Company has numerous outstanding notes payable to various parties. The notes bear interest at rates of 5% - 20% per year and are summarized as follows: SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2023 April 30, 2022 Notes convertible at holder’s option $ 3,042,773 $ 2,980,848 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 2,077,981 1,933,536 Subtotal 5,456,454 5,250,084 Total $ 5,456,454 $ 5,250,084
SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION	The change in fair value of the derivative liabilities on January 31, 2023, was calculated with the following average assumptions using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk-free interest rate Ranging from 0.16% 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout 0 Expected life in years Ranging from 0.25 3.0 Expected life in years Ranging from 0.25 3.0
SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES	Changes in derivative liability during the three months ended January 31, 2023, and April 30, 2022 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES 2023 2022 January 31, April 30, 2023 2022 Balance, beginning of year $ 9,549,640 $ 3,446,738 Derivative liability extinguished (336,418 ) (1,029,141 ) Derivative financial liability arising on the issuance of convertible notes and warrants - Fair value adjustments (4,168,344 ) 7,132,043 Balance, end of period $ 4,504,762 $ 9,549,640

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES	The table below summarizes the fair values of financial liabilities as of January 31, 2023: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2023 Level 1 Level 2 Level 3 Derivative liabilities $ 4,504,762 - - $ 4,504,762 Fair values of financial liabilities as of April 30, 2022, are as follows: Fair Value at Fair Value Measurement Using April 30, 2022 Level 1 Level 2 Level 3 Derivative liabilities $ 9,549,640 - - $ 9,549,640

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Jan. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Significant classes of property and equipment on January 31, 2023, and April 30, 2022, consist of the following: SCHEDULE OF PROPERTY AND EQUIPMENT January 31, 2023 April 30, 2022 Computer equipment, software and furniture $ 213,262 $ 213,262 Less: accumulated depreciation (213,262 ) (213,262 ) Net property and equipment $ - $ -

SCHEDULE OF DISAGGREGATION REVE

SCHEDULE OF DISAGGREGATION REVENUE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2023	Jan. 31, 2022
Product Information [Line Items]
Total	$ 63,670		$ 189,042	$ 187,103
Scenario, Adjustment [Member]
Product Information [Line Items]
Total		$ 60,720
Information Technology [Member]
Product Information [Line Items]
Total	60,120		173,559	168,933
Information Technology [Member] | Scenario, Adjustment [Member]
Product Information [Line Items]
Total		56,134
New World Health Brands [Member]
Product Information [Line Items]
Total	$ 3,550		$ 15,483	$ 18,170
New World Health Brands [Member] | Scenario, Adjustment [Member]
Product Information [Line Items]
Total		$ 4,586

SCHEDULE OF ESTIMATED USEFUL LI

SCHEDULE OF ESTIMATED USEFUL LIFE OF PROPERTY AND EQUIPMENT (Details)	9 Months Ended
	Jan. 31, 2023
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Computer Equipment	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Computer Equipment	7 years
Website Costs [Member]
Property, Plant and Equipment [Line Items]
Computer Equipment	3 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Computer Equipment	5 years

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	9 Months Ended	12 Months Ended
	Jan. 31, 2023	Apr. 30, 2022
Accounting Policies [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	32,350,243	32,350,243
Common stock to be issued	23,333,438	8,916,805

GOING CONCERN MATTERS (Details

GOING CONCERN MATTERS (Details Narrative) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 69,448,432	$ 73,984,686
Working capital deficit	$ 13,438,774	$ 19,327,286

SCHEDULE OF NOTES PAYABLE (Deta

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Short-Term Debt [Line Items]
Subtotal	$ 5,456,454	$ 5,250,084
Total	5,456,454	5,250,084
Notes Convertible at Holder's Option [Member]
Short-Term Debt [Line Items]
Subtotal	3,042,773	2,980,848
Notes Convertible at Company's Option [Member]
Short-Term Debt [Line Items]
Subtotal	335,700	335,700
Non-convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Subtotal	$ 2,077,981	$ 1,933,536

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION (Details)	9 Months Ended
	Jan. 31, 2023
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0.16
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0.2
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	155
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	270
Measurement Input Dividend Payout [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected dividend payout	0
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 years

SCHEDULE OF CHANGES IN DERIVATI

SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES (Details) - USD ($)	3 Months Ended
	Jan. 31, 2023	Apr. 30, 2022
Debt Disclosure [Abstract]
Balance, beginning of year	$ 9,549,640	$ 3,446,738
Derivative liability extinguished	(336,418)	(1,029,141)
Derivative financial liability arising on the issuance of convertible notes and warrants
Fair value adjustments	(4,168,344)	7,132,043
Balance, end of period	$ 4,504,762	$ 9,549,640

NOTES PAYABLE AND DERIVATIVES_2

NOTES PAYABLE AND DERIVATIVES (Details Narrative) - USD ($)	9 Months Ended
	Jan. 31, 2023	Apr. 30, 2022
Debt Instrument [Line Items]
Accrued interest	$ 1,656,450	$ 2,680,787
Decrease of convertible notes	$ 1,024,337
Debt instrument term	6 years
Minimum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	30%
Maximum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	48%

LOANS PAYABLE TO RELATED PART_2

LOANS PAYABLE TO RELATED PARTIES (Details Narrative) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Related Party Transactions [Abstract]
Loans payable to officers and directors	$ 371,753	$ 409,403

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
	Jan. 31, 2023	Jul. 31, 2022	Jan. 31, 2022	Jan. 31, 2023	Jan. 31, 2022	Apr. 30, 2022
Class of Stock [Line Items]
Preferred stock, shares designated	10,000,000			10,000,000		10,000,000
Preferred stock, par value	$ 0.001			$ 0.001		$ 0.001
Common stock, shares authorized	750,000,000			750,000,000		750,000,000
Common stock, par value	$ 0.001			$ 0.001		$ 0.001
Common stock, shares issued	21,581,449			21,581,449		15,128,005
Common stock, shares outstanding	21,581,449			21,581,449		15,128,005
Stock issued during period shares issuance of common shares for cash				3,102,346
Stock issued during period value issuance of common shares for cash				$ 212,500
Stocks issued as note holder incentives, value	$ 190,103		$ 1,296,436
Stock issued during period value issuance of common shares for consulting services	$ 37,595	$ 245,381	$ 25,490
Accredited Investors [Member]
Class of Stock [Line Items]
New issuance, shares				330,179
Stocks issued as note holder incentives, shares				950,833
Stocks issued as note holder incentives, value				$ 83,447
Accredited Investors One [Member]
Class of Stock [Line Items]
Stocks issued as note holder incentives, shares				378,909
Stocks issued as note holder incentives, value				$ 35,000
Consulting [Member]
Class of Stock [Line Items]
Stock issued during period shares issuance of common shares for consulting services				1,928,899
Stock issued during period value issuance of common shares for consulting services				$ 282,981
Common Stock [Member]
Class of Stock [Line Items]
Stocks issued as note holder incentives, shares	747,000		1,620,417
Stocks issued as note holder incentives, value	$ 747		$ 1,841
Stock issued during period shares issuance of common shares for consulting services	333,939	1,594,960	427,235
Stock issued during period value issuance of common shares for consulting services	$ 334	$ 1,595	$ 427
Common Stock [Member] | Six Accredited Investors [Member]
Class of Stock [Line Items]
Stock issued during period shares issuance of common shares for cash					2,726,036
Stock issued during period value issuance of common shares for cash					$ 182,500
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	35,850			35,850		35,850
Preferred stock, par value	$ 100			$ 100		$ 100
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	1,000			1,000
Preferred stock, liquidation and redemption value per share	$ 10,000			$ 10,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	4,200,000			4,200,000
Preferred stock conversion to common stock, shares				1,738,258	1,969,269
Preferred stock conversion to common stock, value				$ 231,396
Series C Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Preferred stock conversion to common stock, value					$ 373,893
Series C Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	4,200,000			4,200,000		4,200,000
Preferred stock, par value	$ 0.001			$ 0.001		$ 0.001
Preferred stock, liquidation and redemption value per share	$ 1			$ 1		$ 1
Series D Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated	2,000,000			2,000,000		2,000,000
Preferred stock, par value	$ 0.001			$ 0.001		$ 0.001
Preferred stock, liquidation and redemption value per share	$ 1			$ 1		$ 1
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock conversion to common stock, shares				141,053	3,194,418
Preferred stock conversion to common stock, value				$ 141,053
Series D Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Preferred stock conversion to common stock, value					$ 975,217
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stocks issued as note holder incentives, shares				1,388,376
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stocks issued as note holder incentives, shares				564,212

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES (Details) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 4,504,762	$ 9,549,640
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 4,504,762	$ 9,549,640

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Jan. 31, 2023	Apr. 30, 2022
Property, Plant and Equipment [Abstract]
Computer equipment, software and furniture	$ 213,262	$ 213,262
Less: accumulated depreciation	(213,262)	(213,262)
Net property and equipment

WARRANTS (Details Narrative)

WARRANTS (Details Narrative)	9 Months Ended
	Jan. 31, 2023 USD ($) shares
Warrants
Warrants vested | shares	9,229,370
Fair value adjustment of warrants | $	$ 211,614

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		9 Months Ended
	Sep. 22, 2016	Jan. 31, 2023	Jan. 31, 2022	Feb. 26, 2015
Rent expenses		$ 49,700	$ 43,200
Promissory Note [Member]
Promissory note amount				$ 50,000
New York County Kings [Member]
Loss on contingent	$ 102,170.82
Lender One [Member]
Debt principal amount		8,365
Promissory note amount		55,125
Lender Two [Member]
Debt principal amount		5,000
Promissory note amount		$ 27,500
Executive Office Space [Member]
Lease expiring date		Jul. 31, 2018
Rent expenses		$ 5,100